ianalumab: Clinical Trials

35 trials of ianalumab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

11 active not recruiting, 9 completed, 6 terminated, 4 recruiting. 16 Phase 2, 13 Phase 3, 7 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 216Completed 6, Active not recruiting 3, Terminated 3, Withdrawn 2, Not yet recruiting 1, Recruiting 1
Phase 313Active not recruiting 8, Recruiting 3, Completed 2
Phase 17Terminated 3, Completed 2, Withdrawn 2

Follow ianalumab: new trials by email Literature Review of ianalumab trials Research Report on ianalumab

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Ianalumab in Addition to Eltrombopag in Pediatric Patients With Primary ITP Who Failed Corticosteroids.
Ianalumab, Eltrombopag - Primary Immune Thrombocytopenia (ITP)
Phase 2Not yet recruitingNovartis Pharmaceuticals362027-02-082026-06-25
A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)
ianalumab, thrombopoietin receptor agonist (TPO-RA) - Primary Immune Thrombocytopenia (ITP), Primary Evans Syndrome (ES)
Phase 2RecruitingNovartis Pharmaceuticals1642026-08-042026-11-17
Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
VAY736, Placebo - Sjögren´s Disease
Phase 3RecruitingNovartis Pharmaceuticals5702026-07-162026-11-09
Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab
Ianalumab - Primary Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia
Phase 2WithdrawnNovartis Pharmaceuticals2026-06-262026-10-15
Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)
Ianalumab - Lupus Nephritis
Phase 3RecruitingNovartis Pharmaceuticals3482025-05-192026-11-09
Pharmacokinetics Study of Ianalumab in Chinese Participants With Autoimmune Diseases
ianalumab - Sjogren Disease, Systemic Lupus Erythematosus
Phase 1WithdrawnNovartis Pharmaceuticals2024-11-252025-01-27
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis
Placebo, Ianalumab - Diffuse Cutaneous Systemic Sclerosis
Phase 2Active not recruitingNovartis Pharmaceuticals2032024-10-092026-11-09
Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease
VAY736 1ml PFS, VAY736 2 ml PFS, VAY736 2ml AI - Sjögrens Disease, Systemic Lupus Erythematosus
Phase 2Active not recruitingNovartis Pharmaceuticals1552024-07-022026-10-14
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
Placebo, Ianalumab - Systemic Lupus Erythematosus
Phase 3RecruitingNovartis Pharmaceuticals5502024-05-212026-11-09
A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.
Ianalumab (VAY736), Placebo - Sjogrens Syndrome
Phase 3Active not recruitingNovartis Pharmaceuticals6122023-10-272026-10-15
A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies
Ianalumab - Primary Immune Thrombocytopenia (ITP)
Phase 2Active not recruitingNovartis Pharmaceuticals412023-08-162026-10-20
Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)
ianalumab, placebo - Systemic Lupus Erythematosus
Phase 3Active not recruitingNovartis Pharmaceuticals2882023-04-212026-10-14
Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)
Ianalumab, Placebo - Systemic Lupus Erythematosus
Phase 3Active not recruitingNovartis Pharmaceuticals4362023-03-022026-10-14
Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)
Ianalumab, Placebo, Corticosteroids - Primary Immune Thrombocytopenia (ITP)
Phase 3Active not recruitingNovartis Pharmaceuticals2262023-02-032026-11-12
A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids
Ianalumab, Eltrombopag, Placebo - Primary Immune Thrombocytopenia
Phase 3Active not recruitingNovartis Pharmaceuticals1522023-02-022026-11-09
A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia
Ianalumab, Placebo - Warm Autoimmune Hemolytic Anemia (wAIHA)
Phase 3Active not recruitingNovartis Pharmaceuticals902022-12-302026-09-11
Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome
VAY736, Placebo - Sjogren Syndrome
Phase 3Active not recruitingNovartis Pharmaceuticals5062022-08-042026-06-17
Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome
VAY736, Placebo - Sjogren Syndrome
Phase 3CompletedNovartis Pharmaceuticals2752022-07-282026-07-07
Biopsy Based Study to Understand Mechanism of Action of Ianalumab in Salivary Glands and Explore Relationships With Clinical Assessments.
Ianalumab - Sjogren Syndrome
Phase 2CompletedNovartis Pharmaceuticals212022-07-272026-02-02
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
ianalumab s.c. q4w, ianalumab s.c. q12w, placebo s.c. - Lupus Nephritis
Phase 3Active not recruitingNovartis Pharmaceuticals4522022-07-142026-10-15

Showing 20 of 35. Sign in to see all of them.

Conditions studied

Lupus Erythematosus, Systemic (7)  ·  Purpura, Thrombocytopenic, Idiopathic (7)  ·  Sjogren's Syndrome (7)  ·  Arthritis, Rheumatoid (3)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (2)  ·  Lupus Nephritis (2)  ·  Autoimmune Diseases (1)  ·  Dry Eye Syndromes (1)  ·  Evans Syndrome (1)  ·  Fatigue (1)  ·  Hepatitis, Autoimmune (1)  ·  Hidradenitis Suppurativa (1)  ·  Idiopathic Pulmonary Fibrosis (1)  ·  Lymphoma, B-Cell, Marginal Zone (1)  ·  Lymphoma, Follicular (1)

Sponsors

Novartis Pharmaceuticals (35)

Countries

United States (24)  ·  Germany (21)  ·  Spain (19)  ·  France (17)  ·  Argentina (15)  ·  China (15)  ·  Hungary (15)  ·  Czechia (14)  ·  Italy (14)  ·  United Kingdom (13)  ·  Japan (12)  ·  South Korea (12)  ·  Taiwan (12)  ·  Australia (10)  ·  India (10)

Results publications

PMID 34398557, PMID 34861168, PMID 35179437, PMID 37722131, PMID 39557617, PMID 40465397, PMID 41217519, PMID 41363800

NIH funding

2023 (7), 2018 (2), 2017 (1), 2025 (1), R01CA177292 (1)